

AMENDMENT

In accordance with 37 C.F.R. § 1.121, please amend the application as follows.

IN THE CLAIMS:

Please cancel claims 4-8, 12-14, 16, 18-20 and 23-27 without prejudice to prosecution of the subject matter of these claims in future amendments in the present application, or in continuation or divisional applications.

Please amend the claims to read as follows:

1. (Amended) An isolated peptide selected from the group consisting of comprising:
(X1)_nEVEKIKTTVKESATEERKLTVPVX2L(X23)_m (SEQ ID NO: 1),
(YD)_nEVAALQVDRKVADEEKQSYDAV(Y2)_m (SEQ ID NO: 2);

wherein

n and m independently represents 0 or 1;

X1, X2 and X3 are independently defined as follows

X1 is GVKETPQQKYQRLHEVQELTT (SEQ ID NO: 3), or
VKETPQQKYQRLHEVQELTT (SEQ ID NO: 4), or
KETPQQKYQRLHEVQELTT (SEQ ID NO: 5), or
ETPQQKYQRLHEVQELTT (SEQ ID NO: 6), or
TPQQKYQRLHEVQELTT (SEQ ID NO: 7), or
PQQKYQRLHEVQELTT (SEQ ID NO: 8), or
QQKYQRLHEVQELTT (SEQ ID NO: 9), or
QKYQRLHEVQELTT (SEQ ID NO: 10), or
KYQRLHEVQELTT (SEQ ID NO: 11), or
YQRLHEVQELTT (SEQ ID NO: 12), or
QRLHEVQELTT (SEQ ID NO: 13), or
RLHEVQELTT (SEQ ID NO: 14), or
LLHEVQELTT (SEQ ID NO: 15), or
LHEVQELTT (SEQ ID NO: 16), or
HEVQELTT (SEQ ID NO: 17), or
EVQELTT (SEQ ID NO: 18), or
VQELTT (SEQ ID NO: 19), or
QELTT (SEQ ID NO: 20), or
ELTT (SEQ ID NO: 21), or
LTT, or
TT, or
T;

X2 is V or L, and

X3 is AKQLAAL (SEQ ID NO: 22), or
AKQLAA (SEQ ID NO: 23), or
AKQLA (SEQ ID NO: 24), or

~~AKQL (SEQ ID NO: 25), or
AKQ, or
AK, or
A;~~

and

Y1 and Y2 are independently defined as follows

~~Y1 is GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or
EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or
KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or
ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or
TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or
PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or
VQKCQRLQIEMNELLN (SEQ ID NO: 32), or
QKCQRLQIEMNELLN (SEQ ID NO: 33), or
KCQRLQIEMNELLN (SEQ ID NO: 34), or
CQRLQIEMNELLN (SEQ ID NO: 35), or
QLQIEMNELLN (SEQ ID NO: 36), or
RLQIEMNELLN (SEQ ID NO: 37), or
LQIEMNELLN (SEQ ID NO: 38), or
QIEMNELLN (SEQ ID NO: 39), or
IEMNELLN (SEQ ID NO: 40), or
EMNELLN (SEQ ID NO: 41), or
MNELLN (SEQ ID NO: 42), or
NELLN (SEQ ID NO: 43), or
ELLN (SEQ ID NO: 44), or
LLN, or
LN, or
N; and~~

~~Y2 is VATVISTAR (SEQ ID NO: 45), or
VATVISTA (SEQ ID NO: 46), or
VATVIST (SEQ ID NO: 47), or
VATVIS (SEQ ID NO: 48), or
VATVI (SEQ ID NO: 49), or
VATV (SEQ ID NO: 50), or
VAT, or
VA, or
V, and~~

derivatives a fragment thereof or a derivative thereof having at least about 90% identity
with SEQ ID NO: 1 ~~or SEQ ID NO: 2.~~

2. (Original) The peptide of claim 1 which is
GVKETPQQKYQRLLEHVQELTTEVEKIKTTVKESATEEKLTPVX2LAKQLAAL
(SEQ ID NO: 51),

wherein X2 is as defined in claim 1.

3. (Original) The peptide of claim 1 which is

GEKETPVQKCQRLQIEMNELLNEVAALQVDRKVADEEKQSYDAVVATVISTAR
(SEQ ID NO: 52).

4 - 8. Canceled.

9. (Original) The peptide of claim 1 capable of modulating cellular proliferation.

10. (Original) The peptide of claim 1 capable of inhibiting cellular proliferation.

11. (Original) The peptide of claim 10 capable of selective inhibition of cancerous cells.

12 - 14. (Cancelled).

15. (Original) A composition comprising a peptide of claim 1 in admixture with a pharmaceutically acceptable carrier.

16. (Cancelled).

17. (Original) A method for inhibiting cellular proliferation comprising delivering to a target cell an effective amount of an isolated peptide of claim 1 or a nucleic acid encoding said peptide.

18-20 (Cancelled).

21. (Original) The method of claim 17 wherein said target cell is a tumor cell.

22. (Original) The method of claim 21 wherein said tumor cell is a cancer cell.